News

CURE1d
FDA Approves Cabometyx, Another Treatment for Neuroendocrine Tumors
The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.
CURE2d
Phase 3 Trial Leads to FDA Approval of Cabometyx in Neuroendocrine Tumors
Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...
Targeted Oncology5d
Site of Neuroendocrine Tumors Affects Outcomes With Cabozantinib
Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.